KRAS and breast carcinoma: Thus, expression of YB-1 in cytoplasmic and nuclear fractions was tested after irradiation in tumor cells from different origins, i.e., in the KRAS(G13D)-mutated breast cancer cell line MDA-MB-231, in the KRAS(Q61H)-mutated NSCLC cell line H460, and in the KRAS(G12V)-mutated NSCLC cell line A549.